Literature DB >> 16033615

Persistence with antimuscarinic therapy in patients with overactive bladder.

F Haab1, D Castro-Diaz.   

Abstract

Overactive bladder (OAB) is a chronic condition, which impacts patients' health and quality of life. The primary symptoms of OAB are distressing and may interfere with work, psychosocial and sexual functioning. OAB also is associated with increased risk of urinary tract infections, fractures from falls, skin infections and depression. Patient's concerns about the effects of incontinence on lifestyle highlight the need to restore continence. The mainstay of treatment is antimuscarinic drug therapy, which may often produce only modest reductions in OAB symptoms and may be accompanied by bothersome adverse effects, leading to poor adherence to prescribed medications. Successful treatment of OAB depends on persistence with the prescribed medication, and efficacy and tolerability are key influencers of persistence. New antimuscarinic agents are now available for treating OAB that significantly improve symptoms of incontinence, urgency and frequency with few adverse effects. An improved efficacy and tolerability profile should result in greater patient satisfaction and persistence with therapy during long-term therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16033615     DOI: 10.1111/j.1368-5031.2005.00617.x

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  20 in total

Review 1.  Tolterodine in the Treatment of Male LUTS.

Authors:  Mauro Gacci; Arcangelo Sebastianelli; Matteo Salvi; Riccardo Schiavina; Eugenio Brunocilla; Giacomo Novara; Cosimo De Nunzio; Andrea Tubaro; Matthias Oelke; Stavros Gravas; Marco Carini; Sergio Serni
Journal:  Curr Urol Rep       Date:  2015-09       Impact factor: 3.092

2.  Success rates, quality of life, and feasibility of sacral nerve stimulation in elderly patients: 1-year follow-up.

Authors:  Roberto Angioli; Roberto Montera; Francesco Plotti; Alessia Aloisi; Eva Montone; Marzio Angelo Zullo
Journal:  Int Urogynecol J       Date:  2012-09-08       Impact factor: 2.894

3.  Antimuscarinic persistence patterns in newly treated patients with overactive bladder: a retrospective comparative analysis.

Authors:  Antoni Sicras-Mainar; Javier Rejas; Ruth Navarro-Artieda; Alba Aguado-Jodar; Amador Ruiz-Torrejón; Jordi Ibáñez-Nolla; Marion Kvasz
Journal:  Int Urogynecol J       Date:  2013-11-06       Impact factor: 2.894

4.  Patient-reported most bothersome symptoms in OAB: post hoc analysis of data from a large, open-label trial of solifenacin.

Authors:  Peter K Sand; William D Steers; Roger Dmochowski; Masakazu Andoh; Sergio Forero-Schwanhaeuser
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2009-03-10

Review 5.  Purinoceptors as therapeutic targets for lower urinary tract dysfunction.

Authors:  Anthony P D W Ford; Joel R Gever; Philip A Nunn; Yu Zhong; Joseph S Cefalu; Michael P Dillon; Debra A Cockayne
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 6.  Muscarinic receptors in the bladder: from basic research to therapeutics.

Authors:  Sharath S Hegde
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

7.  Will the evolution of overactive bladder delivery systems increase patient compliance?

Authors:  Nirit Rosenblum
Journal:  Rev Urol       Date:  2009

8.  Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.

Authors:  Steven E Swift; Paul Siami; Sergio Forero-Schwanhaeuser
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

Review 9.  Pharmacotherapy of urinary incontinence.

Authors:  Anastasios Athanasopoulos; Petros Perimenis
Journal:  Int Urogynecol J Pelvic Floor Dysfunct       Date:  2008-11-12

10.  Cost-effectiveness analysis of antimuscarinics in the treatment of patients with overactive bladder in Spain: a decision-tree model.

Authors:  Salvador Arlandis-Guzman; Carlos Errando-Smet; Jeffrey Trocio; Daniel Arumi; Javier Rejas
Journal:  BMC Urol       Date:  2011-05-20       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.